In vitro and in vivo Antidiabetic Activity of Ag Nanoparticles Mediated from Gymnemic acid I and II

Abstract:

Background: Gymnema sylvestre is traditionally used to treat diabetes in Asia. The triterpenoid glycosides Gymnemic acid-I (GA-I) and Gymnemic acid-II are the main biologically active components (GA-II). Glide has yet to be used to define the mechanisms of action of drugs, nevertheless. Materials and methods: To dock to the active site of protein tyrosine phosphate 1B, the GA-I and GA-II compounds were used. The identical nanoparticles were produced using the straightforward centrifugation green synthesis technique using silver nitrate at a predetermined temperature. The created nanoparticles have undergone XRD, UV, FESEM, TEM, DLS, and Zeta potential characterization. Using the PTP 1B assay and a diabetic animal model induced by streptozotocin, the anti-hyperglycemic activity of green-produced nanoparticles was determined in vitro and in vivo. The GA-I-induced AgNPs showed exceptional PTP 1B enzyme inhibitory effectiveness among other medicines. Rats with diabetes are administered 100 mg/kg and 200 mg/kg of GA-I mediated AgNPs, 100 mg/kg and 200 mg/kg of GA-II mediated AgNPs and 50 mg/kg of metformin. Results: Blood glucose levels were significantly decreased (p 0.001) at a dose of 200 mg/kg (b.wt. p.o.) of GA-I mediated AgNPs compared to the GA-II mediated AgNP treated group. Conclusion: Hence, it may indicate that GA-I mediated AgNPs be exploited as prospective nanomedicine for treating type-2 diabetes mellitus.

Keywords: Gymnemic acid-I, Gymnemic acid-II, Gymnema sylvestre, Molecular docking, PTP 1B, Antihyperglycemic activity.